TASE:NVLGHealthcare
Novolog (TASE:NVLG) Stock Revenue Growth Meets A Sharp Profit Squeeze
Novolog (Pharm-Up 1966) comes into this earnings season with the stock at ₪0.74 and a mixed recent run, with a decline over the past week but a gain over the past month. The headline this quarter is not growth; it is the squeeze on profitability. Q2 2026 revenue of ₪451.9m was paired with only ₪0.6m in net income and a trailing twelve month loss, which keeps the pressure on a dividend that is not covered by earnings.
Is Novolog (Pharm-Up 1966) trading at a genuine discount on its low 0.2x...